Royalty Pharma plc (RPRX) stock analysis

In our weekly check, Royalty Pharma plc is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.

About Royalty Pharma plc

Royalty Pharma plc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RPRX.

What our checks show for RPRX

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-10

Similar companies

CORT · KNSA · LQDA

Questions

What grade does Royalty Pharma plc (RPRX) have?

In our weekly check, Royalty Pharma plc is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of RPRX stock?

This week's biggest flags for Royalty Pharma plc: High debt, Gross margin falling, Margins falling. In total 5 of 25 checks show a warning or a red flag.

What does Royalty Pharma plc do?

Royalty Pharma plc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RPRX.

When does Royalty Pharma plc report earnings next?

The next earnings report is expected on 2027-02-10. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis